Cortico-striatal cyclic AMP-phosphodiesterase-4 signalling and stereotypy in the deer mouse: Attenuation after chronic fluoxetine treatment

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 3, 2009, Pages 514-520

  Korff, Schaun ^a   Stein, Dan J ^b   Harvey, Brian H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

5 HT1A; cAMP; Deer mouse; Fluoxetine; PDE4; Pre frontal cortex; Serotonin; Spontaneous stereotypy; Striatum

Indexed keywords

CYCLIC AMP; FLUOXETINE; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; MOUSE; NONHUMAN; PEROMYSCUS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOTYPY;

ANIMALS; CORPUS STRIATUM; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FLUOXETINE; MICE; PEROMYSCUS; PREFRONTAL CORTEX; SIGNAL TRANSDUCTION; STEREOTYPED BEHAVIOR;

ANIMALIA; MUS; PEROMYSCUS; PEROMYSCUS MANICULATUS;

EID: 62249151743     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.01.025     Document Type: Article

References (48)

1. APA, American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition (2000), American Psychiatric Press, Washington, USA 417-423
2. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
3. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
4. Baumann M.H., Clark R.D., and Rothman R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90 (2008) 208-217
5. Beavo J.A. Cylic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
6. Bedingfield J.B., Calder L.D., Thai D.K., and Karler R. The role of the striatum in the mouse in behavioural sensitization to amphetamine. Pharmacol Biochem Behav 56 (1997) 305-310
7. Bergqvist P.B., Bouchard C., and Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry 45 (1999) 164-174
8. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63 (1999) 1-38
9. Cote M., Payet M.D., Rousseau E., Guillon G., and Gallo-Payet N. Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human glomerulosa cells. Endocrinology 140 (1999) 3594-3601
10. Dlaboga D., Hajjhhussein H., and O'Donnell J.M. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res 1096 (2006) 104-112
11. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disorders 4 (2002) 183-194
12. D'Sa C., Eisch A.J., Bolger G.B., and Duman R.S. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci 22 (2005) 1463-1475
13. Dubois B., Verin M., Teixeira-Ferreira C., Sirigu A., and Pillon B. Functions of the prefrontal cortex. In: Thierry A.-M., Glowinski J., Goldman-Rakic P.S., and Christen Y. (Eds). Motor and Cognitive functions of the prefrontal cortex (1994), Springer-Verlag, Berlin 1-16
14. Ellis S.M., and Steyn H.S. Practical significance (effect sizes) versus or in combination with statistical significance (P values). Manag Dyn 12 (2003) 51-53
15. El Mansari M., and Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 362-373
16. Ernst A.M., and Smelik P.G. Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats. Experientia 22 (1966) 837-838
17. Garner J.P. Stereotypies and other abnormal repetitive behaviours: potential impact on validity, reliability, and replicability of scientific outcomes. ILAR J 46 (2005) 106-117
18. Guldin W.O., Pritzel M., and Markowitsch H.J. Prefrontal cortex of the mouse defined as cortical projection area of the thalamic mediodorsal nucleus. Brain Behav Evol 19 (1981) 93-107
19. Halene T.B., and Siegel S.J. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia?. Drug Discov Today 12 (2007) 870-878
20. Hillegaart V., Magnusson O., and Ahlenius S. A9 and A10 dopamine nuclei as a site of action for effects of 8-OH-DPAT on locomotion in the rat. Pharmacol Biochem Behav 67 (2000) 55-63
21. Houslay M.D., and Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22 (1997) 217-224
22. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44 (1998) 225-342
23. Hudson C.J., Young L.T., Li P.P., and Warsh J.J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13 (1993) 278-293
24. Kelly A.E. Neural integrative activities of nucleus accumbens subregions in relation to learning and motivation. Psychobiology 27 (1999) 198-213
25. Korff S., and Harvey B.H. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 29 (2006) 371-390
26. Korff S., Stein D.J., and Harvey B.H. Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 32 (2008) 348-355
27. Kuczenski R., and Segal D. Concomitant characterization of behavioural and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9 (1989) 2051-2065
28. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioural responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15 (1995) 1308-1317
29. Lewis M.H., Tanimura Y., Lee L.W., and Bodfish J.W. Animal models of restricted repetitive behaviour in autism. Behav Brain Res 176 (2007) 66-74
30. Lourenco C.M., Kenk M., Beanlands R.S., and DaSilva J.N. Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart. Life Sci 79 (2006) 356-364
31. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat Med 7 (2001) 541-547
32. Marazziti D., Perez J., and Cassano G.B. Is obsessive-compulsive disorder caused by a second-messenger imbalance?. CNS Spectr. 6 (2001) 206-209
33. Miró X., Pérez-Torres S., Artigas F., Puigdomènech P., Palacios J.M., and Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 43 (2002) 1148-1157
34. Nibuya M., Nester E.J., and Duman R.S. Chronic antidepressant admininstration increase the expression of cAMP response element binding protein (CREB) in the rat hippocampus. J Neurosci 16 (1996) 2365-2372
35. Ozawa H., and Rasenick M.M. Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs ot the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem 56 (1991) 330-338
36. Perez J., Tardito D., Ravizza L., Racagni G., Mori S., and Maina G. Altered cAMP-dependent protein kinase A in platelets of patients with obsessive-compulsive disorder. Am J Psychiatry 157 (2000) 284-286
37. Powell S.B., Newman H.A., Pendergast J.F., and Presti M.H. A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 66 (1999) 355-363
38. Presti M.F., and Lewis M.H. Striatal opioid peptide content in an animal model of spontaneous stereotypic behaviour. Behav Brain Res 157 (2005) 363-368
39. Rausch J.L., Johnson M.E., Kasik K.E., and Stahl S. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology 31 (2006) 2274-2280
40. Rich T.C., Tse T.E., Rohan J.G., Schaack J., and Karpen J.W. In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors. J Gen Physiol 118 (2001) 63-78
41. Soderling S.H., and Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12 (2000) 174-179
42. Stein D.J. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 47 (2000) 296-304
43. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19 (1999) 610-618
44. Tibbo P., and Warneke L. Obsessive compulsive disorder in schizophrenia: epidemiological and biological overlap. J Psychiatry Neurosci 24 (1999) 15-24
45. Torphy T.J., and Cielinski L.B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isoenzyme in canine tracheal smooth muscle. Mol Pharmacol 37 (1990) 206-214
46. Turner M. Annotation: repetitive behaviour in autism: a review of psychological research. J Child Psychol Psychiatry 40 (1999) 839-849
47. Ye Y., Jackson K., and O'Donnell J.M. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 74 (2000) 1257-1262
48. Zhao Y., Zhang H.T., and O'Donnell J.M. Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307 (2003) 246-253